Fig. 5. Rsad2 knockdown mDCs show reduced antitumor activity in a murine model of lung metastasis.

Inhibition of pulmonary metastasis by vaccination with B16F10 tumor lysate-pulsed DCs. C57BL/6 mice received viable B16F10 cells (1 × 10⁶) via the lateral tail vein to establish a pulmonary metastasis model. Mice were then inoculated twice intravenously with B16F10 tumor lysate-pulsed DCs (1 × 10⁶) (once on day 3 and once on day 10 post-tumor cell tumor injection). Mice were killed on day 21 a DC vaccination schedule. b Tumor nodules were counted 21 days after killing tumor-bearing mice. Data represent the mean number of nodules ± SEM (n = 10 mice per group). c Splenocytes from DC-vaccinated mice were stained with the anti-CD8 and anti-CD3 antibody. The graph show the number of CD8⁺/CD3⁺ T cells in each mice group, expressed as the mean ± SEM (n = 7 per each group). d Splenocytes from DC-vaccinated mice were stained with a FITC-anti-CD8 antibody, fixed with 2% formaldehyde, permeabilized with 0.5% saponin, and incubated with PE-anti-IFN-γ. The graph shows the percentage of the IFN-γ⁺CD8⁺ T cells in each mice group, expressed as the mean ± SEM (n = 7 per each group). *P < 0.05, **P < 0.01, and ***P < 0.001